factor viia การใช้

• It is treated with recombinant factor VIIa ( NovoSeven or AryoSeven ).
• The implants are porous chambers containing a substance that converts Factor VII to Factor VIIa.
• Tissue factor binds to circulating factor VIIa.
• Factor VIIa was 60 percent higher.
• Together with factor VIIa, tissue factor forms the tissue factor or extrinsic pathway of coagulation.
• They can be treated with infusions of Factor VIIa instead, but that is expensive and the protein disintegrates quickly.
• In stage 1, Factor VII binds to the transmembrane protein TF on the surface of cells and is converted to Factor VIIa.
• Recombinant factor VIIa ( rFVIIa ) is not, as of 2012, supported by the evidence for most cases of major bleeding.
• Lusher later conducted the first studies on the use of recombinant factor VIIa in the treatment of bleeding episodes in patients with hemophilia.
• The monkey, which had three implants in its abdomen, generated Factor VIIa for a month before the implants were removed for inspection.
• The complex of TF with factor VIIa activates factor IX and catalyzes the conversion of the inactive protease factor X into the active protease factor Xa.
• The complex of factor VIIa with TF catalyzes the conversion of factor IX and factor X into the active proteases, factor IXa and factor Xa, respectively.
• Factor X can be activated by both the factor VIIa-tissue factor complex of the extrinsic coagulation pathway and by the tenase complex of the intrinsic pathway.
• Upon exposure to blood and platelets, TF binds with activated factor VIIa ( normally present in trace amounts in the blood ), forming the extrinsic tenase complex.
• But blood samples showed the implants converted a natural protein from the animals into useful amounts of an activated form, called Factor VIIa, that is now used in hemophilia treatment.
• Thus blood transfusion is frequent in the management of patients with this kind of pregnancy, with others even using tranexamic acid and recombinant factor VIIa, which both minimize blood loss.
• Note that one of factor VIIa's domains, GLA domain, binds in the presence of calcium to negatively charged phospholipids, and this binding greatly enhances factor VIIa binding to tissue factor.
• Note that one of factor VIIa's domains, GLA domain, binds in the presence of calcium to negatively charged phospholipids, and this binding greatly enhances factor VIIa binding to tissue factor.
• Recombinant factor VIIa, marketed under the trade names " AryoSeven " and " NovoSeven ", is used for people with hemophilia ( with Factor VIII or IX deficiency ) who have developed antibodies against replacement coagulation factor.
• It is processed to remove the signal peptide, glycosylated and then cleaved by factor XIa ( of the contact pathway ) or factor VIIa ( of the tissue factor pathway ) to produce a two-chain form where the chains are linked by a disulfide bridge.